TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15320664

Group type: EXPERIMENTAL
Intervention: Swiss ball training (2 sessions per week for 6 weeks)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (n = 10)
Number of subjects: 18
Study: 11453262

Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol
Number of subjects: 126

Group type: COMPARATOR
Intervention: Intravaginal dinoprostone
Number of subjects: 126
Study: 9241338

Group type: COMPARATOR
Intervention: Nitrous oxide in oxygen (2:1) supplemented with fentanyl (Control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Halothane at 0.25 MAC (0.19%)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Halothane at 0.5 MAC (0.37%)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Halothane at 1.0 MAC (0.74%)
Number of subjects: 60
Study: 8382899

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) 15,000 aXaU/day sc
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 36
Study: 2941291

Group type: EXPERIMENTAL
Intervention: 250 mg ciprofloxacin (n = 85)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: 500 mg ciprofloxacin (n = 79)
Number of subjects: 164
Study: 28353542

Group type: EXPERIMENTAL
Intervention: Culturally relevant cardiovascular health promotion intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 26892847

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT) with discontinuation of mADM (n=128)
Number of subjects: 249

Group type: COMPARATOR
Intervention: Mindfulness-based cognitive therapy (MBCT) + maintenance antidepressant medication (mADM) (n=121)
Number of subjects: 249
Study: 24913704

Group type: EXPERIMENTAL
Intervention: Manual Acupuncture (MA)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Electro-Acupuncture (EA)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 303
Study: 22337509

Group type: EXPERIMENTAL
Intervention: Sub-threshold spinal cord stimulation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Supra-threshold spinal cord stimulation
Number of subjects: 10

Group type: COMPARATOR
Intervention: No stimulation (control)
Number of subjects: 10
Study: 20129568

Group type: EXPERIMENTAL
Intervention: Remote ischemic periconditioning (RIPC)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: RIPC and morphine
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study: 18276895

Group type: EXPERIMENTAL
Intervention: Entity condition (fixed intelligence)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Incremental condition (improvable intelligence)
Number of subjects: 0
Study: 16868056

Group type: COMPARATOR
Intervention: Behavioral intervention promoting a diet with 28% energy from total fat, less than 8% from saturated fat, 9% or less from polyunsaturated fat, and less than 75 mg cholesterol per 1000 kcal.
Number of subjects: 354

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 354
Study: 12620262

Group type: EXPERIMENTAL
Intervention: 3% VARIHES or ISOHES + 4% albumin (1:1)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma (FFP)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 3% VARIHES or ISOHES
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 4% albumin
Number of subjects: 29
Study: 10856147

Group type: EXPERIMENTAL
Intervention: Inhaled indomethacin (50 mg/d)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 9126694

Group type: EXPERIMENTAL
Intervention: Meropenem (1,000 mg iv every 8 hours)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Clindamycin (900 mg every 8 hours) plus Tobramycin (5 mg/[kg.d] in three divided doses) iv
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 215

Group type: COMPARATOR
Intervention: Clindamycin/tobramycin
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 215
Study: 1493841

Group type: EXPERIMENTAL
Intervention: Temazepam (15 mg) plus ethanol (peak blood concentration of 11 mmol.l‐1)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Temazepam alone
Number of subjects: 6

Group type: COMPARATOR
Intervention: Ethanol alone
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Combination of temazepam and ethanol
Number of subjects: 6
Study: 4065191

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg p.o.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29565752

Group type: EXPERIMENTAL
Intervention: Body Project
Number of subjects: 20

Group type: COMPARATOR
Intervention: Psychoeducational control group
Number of subjects: 20
Study: 27092785

Group type: EXPERIMENTAL
Intervention: OFS + tamoxifen
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: OFS + exemestane
Number of subjects: 86

Group type: COMPARATOR
Intervention: tamoxifen alone
Number of subjects: 86
Study: 24337589

Group type: EXPERIMENTAL
Intervention: CKD-810
Number of subjects: 44

Group type: COMPARATOR
Intervention: Taxotere
Number of subjects: 44
Study: 22549656

Group type: EXPERIMENTAL
Intervention: MPK featuring a microprocessor‐controlled stance and swing phase (MPKA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Mechanically controlled prosthesis
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: MPK featuring a microprocessor‐controlled stance phase (MPKB)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Mechanical knee joint condition
Number of subjects: 30
Study: 20855682

Group type: EXPERIMENTAL
Intervention: Patients with OSAS
Number of subjects: 59

Group type: COMPARATOR
Intervention: Patients with severe OSAS
Number of subjects: 59
Study: 18520792

Group type: EXPERIMENTAL
Intervention: Schedule-dependent low-dose paclitaxel for radiosensitization
Number of subjects: 27
Study: 15869701

Group type: EXPERIMENTAL
Intervention: Dynamic facial expressions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-static, multi-static, dynamic, and first-last modes
Number of subjects: 0
Study: 12790886

Group type: EXPERIMENTAL
Intervention: Surgical therapy (anteromesial temporal lobe resection)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Continued medical therapy
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Localized neocortical resections
Number of subjects: 64
Study: 10348786

Group type: EXPERIMENTAL
Intervention: AZ (5 mg/kg/day) alone (ALONE)
Number of subjects: 10

Group type: COMPARATOR
Intervention: AZ (5 mg/kg/day) and ATQ (30 mg/kg/day) simultaneously (SIM)
Number of subjects: 10
Study: 7554041

Group type: COMPARATOR
Intervention: Oral tamoxifen at 10 mg twice a day
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Percutaneous 4-OH-TAM at 0.5 mg/day
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Percutaneous 4-OH-TAM at 1 mg/day
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Percutaneous 4-OH-TAM at 1 mg/day to a large cutaneous area excluding the breasts
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Percutaneous 4-OH-TAM at 2 mg/day to a large skin area excluding the breasts
Number of subjects: 5
Study: 1842981

Group type: EXPERIMENTAL
Intervention: Steroid treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no steroid treatment)
Number of subjects: 0
Study: 7041728

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of vasopressin (40 U/h)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of vasopressin
Number of subjects: 60
Study: 31421033

Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 30045346

Group type: EXPERIMENTAL
Intervention: 6 months of anti tubercular therapy (ATT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 12 months of anti tubercular therapy (ATT)
Number of subjects: 100
Study: 28282746

Group type: EXPERIMENTAL
Intervention: Performing the action (acting)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Observing the action
Number of subjects: 80
Study: 26822982

Group type: EXPERIMENTAL
Intervention: Strong Hearts, Healthy Communities
Number of subjects: 16

Group type: COMPARATOR
Intervention: Strong Hearts, Healthy Women
Number of subjects: 16
Study: 25539714

Group type: EXPERIMENTAL
Intervention: Systematic Voiding Programme (SVP)
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: SVP plus supported implementation (SVP+)
Number of subjects: 413

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: SVP and SVP+ (combined)
Number of subjects: 413
Study: 22506794

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Applied relaxation (AR)
Number of subjects: 57
Study: 19166765

Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine
Number of subjects: 40

Group type: COMPARATOR
Intervention: 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 40
Study: 17059423

Group type: EXPERIMENTAL
Intervention: ART-123 (0.06 mg kg(‐1) for 30 min, once daily)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Heparin sodium (8 U kg(‐1) h(‐1) for 24 h)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: ART-123
Number of subjects: 234

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 234
Study: 15123532

Group type: EXPERIMENTAL
Intervention: Bezafibrate 400 mg retard once a day
Number of subjects: 303

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 303
Study: 12575238

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 40
Study: 9514431

Group type: EXPERIMENTAL
Intervention: Vaginal deliveries (number of deliveries)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Perineal position at rest and during simulated defecation
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Pudendal nerve terminal motor latency
Number of subjects: 144
Study: 7648243

Group type: EXPERIMENTAL
Intervention: 10 mg bisoprolol
Number of subjects: 59

Group type: COMPARATOR
Intervention: 50 mg atenolol
Number of subjects: 59
Study: 2523665

Group type: EXPERIMENTAL
Intervention: Isradipine (1.25, 2.5, and 5.0 mg twice daily)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Isradipine (monotherapy)
Number of subjects: 600
Study: 66240

Group type: EXPERIMENTAL
Intervention: Oral oxymorphone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intramuscular oxymorphone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular morphine
Number of subjects: 0
Study: 31350753

Group type: EXPERIMENTAL
Intervention: Electrolyte beverage (EB) - kCal: 120, Na: 840 mg, K: 320 mg, Mg: 5 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Electrolyte beverage (EB)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo beverage (PB) - kCal: 5, Na: 35 mg
Number of subjects: 9
Study: 28165543

Group type: EXPERIMENTAL
Intervention: lamivudine 100 mg/d + adefovir dipivoxil 10 mg/d
Number of subjects: 120

Group type: COMPARATOR
Intervention: entecavir 0.5 mg/d
Number of subjects: 120
Study: 26390898

Group type: EXPERIMENTAL
Intervention: 3-month program of exercise training and nutrition
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Leptin stimulation in NK-92 cells
Number of subjects: 32
Study: 23362880

Group type: EXPERIMENTAL
Intervention: Early oral feeding from day 1
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nil by mouth until day 3, then oral diet (Control)
Number of subjects: 100
Study: 20621564

Group type: EXPERIMENTAL
Intervention: Nurse Based Motivational Interviewing (NBMI)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Care as usual (LIFE)
Number of subjects: 112
Study: 19036067

Group type: EXPERIMENTAL
Intervention: Baseline fibrinogen
Number of subjects: 785

Group type: EXPERIMENTAL
Intervention: Fibrinogen at the start of a 6-month interval
Number of subjects: 785

Group type: COMPARATOR
Intervention: Risk models with and without fibrinogen
Number of subjects: 785
Study: 17853750

Group type: EXPERIMENTAL
Intervention: Abdominal acupuncture plus Madopa
Number of subjects: 60

Group type: COMPARATOR
Intervention: Madopa (Control)
Number of subjects: 60
Study: 15172920

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (diet and physical activity)
Number of subjects: 0
Study: 11335704

Group type: EXPERIMENTAL
Intervention: H(2)(15)O-PET during Tower of London (TOL) task
Number of subjects: 2
Study: 9549168

Group type: EXPERIMENTAL
Intervention: Doxazosin (4 mg daily)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 7522395

Group type: EXPERIMENTAL
Intervention: G-CSF 10 micrograms/kg
Number of subjects: 2

Group type: COMPARATOR
Intervention: G-CSF 5 micrograms/kg
Number of subjects: 2

Group type: COMPARATOR
Intervention: Cyclophosphamide 4 g/m2 + G-CSF 5 micrograms/kg
Number of subjects: 2
Study: 3139705

Group type: EXPERIMENTAL
Intervention: Protein-polysaccharide vaccine (23 volunteers)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control preparation containing polysaccharides only (24 volunteers)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Disease (serogroup B serotype 15 meningococcal disease, 13 survivors)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Convalescent-phase sera from disease survivors
Number of subjects: 47
Study: 29265454

Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment (oral hygiene instructions + scaling and root planing using ultrasound and Gracey curettes)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (oral hygiene instructions + supragingival removal of plaque and calculus using ultrasound)
Number of subjects: 90
Study: 27569442

Group type: COMPARATOR
Intervention: MAP (cisplatin 120 mg/m2, doxorubicin 37.5 mg/m2 on days 1 and 2, high-dose methotrexate 12 g/m2)
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: MAPIE (MAP plus high-dose ifosfamide 14 g/m2 and etoposide 100 mg/m2)
Number of subjects: 618

Group type: COMPARATOR
Intervention: MAP
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: MAPIE
Number of subjects: 618
Study: 25405132

Group type: EXPERIMENTAL
Intervention: 300 mg elemental magnesium (as magnesium sulfate ‐MgSo4‐) daily for 3 months
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 22430217

Group type: EXPERIMENTAL
Intervention: HP cream (1.5% w/w hyperforin-rich extract)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 20
Study: 20831681

Group type: EXPERIMENTAL
Intervention: Saffron 30 mg/day (15 mg twice per day)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo (two capsules per day)
Number of subjects: 46
Study: 19083405

Group type: EXPERIMENTAL
Intervention: Creatine (4 g/d for 2 years)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 17169938

Group type: EXPERIMENTAL
Intervention: Behavioral intervention group
Number of subjects: 80

Group type: COMPARATOR
Intervention: Psychoeducational control group
Number of subjects: 80
Study: 14560218

Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) 325 mg daily
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Clopidogrel (Clop) 75 mg daily
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Cilostazol (Cilo) 100 mg twice daily
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: ASA + Clop
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: ASA + Cilo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Clop + Cilo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Clop + ASA
Number of subjects: 21
Study: 11762813

Group type: EXPERIMENTAL
Intervention: Oxaliplatin plus cyclophosphamide (OXAC)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Cisplatin plus cyclophosphamide (CPC)
Number of subjects: 177
Study: 9421356

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with cyclophosphamide/methotrexate/S-fluorouracil (CMF) (n = 130)
Number of subjects: 277

Group type: COMPARATOR
Intervention: No post-operative treatment (n = 147)
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with CMF in women with p53-positive tumours
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with CMF in women with p53-negative tumours
Number of subjects: 277
Study: 8215478

Group type: EXPERIMENTAL
Intervention: Granisetron plus hydroxyzine hydrochloride (Group G/H)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Granisetron alone (Group G)
Number of subjects: 0
Study: 3691592

Group type: EXPERIMENTAL
Intervention: Nicardipine (90 mg/day) + Propranolol (120 mg/day)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Propranolol (120 mg/day)
Number of subjects: 67
Study: 29911513

Group type: EXPERIMENTAL
Intervention: Iron deficiency (ID)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Anaemia
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Iron-deficiency anaemia (IDA)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Dietary habits
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Consumption of fruits and vegetables
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Mother's education
Number of subjects: 330
Study: 28277352

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (25 mg every 8 hours) plus intravenous infusion of 2 L isotonic solution
Number of subjects: 184

Group type: COMPARATOR
Intervention: Hydration alone (control)
Number of subjects: 184
Study: 25816382

Group type: EXPERIMENTAL
Intervention: Ambient ED environment
Number of subjects: 70

Group type: COMPARATOR
Intervention: Traditional ED environment
Number of subjects: 70
Study: 24156455

Group type: EXPERIMENTAL
Intervention: Ademetionine 1, 4-butanedisulfonate combined with polyene phosphatidyl choline
Number of subjects: 62

Group type: COMPARATOR
Intervention: Compound glycyrrhizin
Number of subjects: 62
Study: 21914628

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 431

Group type: COMPARATOR
Intervention: Infliximab to Abatacept
Number of subjects: 431
Study: 19016987

Group type: EXPERIMENTAL
Intervention: Endoscopic saphenous vein harvest (EVH)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional open saphenous vein harvest (OVH)
Number of subjects: 120
Study: 17022378

Group type: EXPERIMENTAL
Intervention: Pycnogenol (50 mg capsules, 3 times daily for a total of 150 mg daily for 4 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no treatment during the observation period)
Number of subjects: 30
Study: 14672470

Group type: EXPERIMENTAL
Intervention: Intravenous ampicillin, 2 g every 6 hours, and gentamicin, 1.5 mg/kg every 8 hours, followed by one additional scheduled dose postpartum (study group)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Intravenous ampicillin, 2 g every 6 hours, and gentamicin, 1.5 mg/kg every 8 hours, continued until afebrile and asymptomatic for 24 hours (control group)
Number of subjects: 292
Study: 10723818

Group type: COMPARATOR
Intervention: Nicotine patch
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nicotine oral inhaler
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination NRT
Number of subjects: 0
Study: 9369626

Group type: EXPERIMENTAL
Intervention: Transparent polyurethane dressing (N = 49)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sterile gauze dressing (N = 31)
Number of subjects: 80
Study: 31407970

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 30562083

Group type: EXPERIMENTAL
Intervention: Drug-Coated Balloon (DCB) angioplasty
Number of subjects: 263

Group type: COMPARATOR
Intervention: Plain balloon angioplasty
Number of subjects: 263
Study: 26689885

Group type: EXPERIMENTAL
Intervention: Subcutaneous unfractionated heparin 5000 units three-times a day
Number of subjects: 50

Group type: COMPARATOR
Intervention: Continuous intravenous infusion of unfractionated heparin 625 IU/h
Number of subjects: 50
Study: 25076007

Group type: EXPERIMENTAL
Intervention: Prehabilitation
Number of subjects: 77

Group type: COMPARATOR
Intervention: Rehabilitation
Number of subjects: 77
Study: 22525915

Group type: EXPERIMENTAL
Intervention: Paracervical block (2 mL 1% buffered lidocaine at tenaculum site + 18 mL at four sites)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Paracervical block
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham (no injection)
Number of subjects: 120
Study: 18377682

Group type: EXPERIMENTAL
Intervention: FOS (10 g once daily for 5 weeks)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: BLEND (50% FOS and 50% acacia gum; 10 g once daily for 5 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Maltodextrin (10 g once daily for 2 weeks during run-in phase)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Self-reported general wellbeing
Number of subjects: 20
Study: 16488689

Group type: EXPERIMENTAL
Intervention: Phosphorylcholine-coated oxygenator
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standard oxygenator (control group)
Number of subjects: 39
Study: 14708414

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine (2 mg/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 5% tramadol (2 mg/kg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Acetaminophen (20 mg/kg) administered rectally if pain score > 3/10
Number of subjects: 20
Study: 10976598

Group type: EXPERIMENTAL
Intervention: Contrastive properties (1 transparent and 1 opaque object)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Consistent properties (2 transparent objects)
Number of subjects: 2
Study: 9291242

Group type: EXPERIMENTAL
Intervention: Eptifibatide (INTEGRILIN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 8325058

Group type: EXPERIMENTAL
Intervention: Protriptyline
Number of subjects: 14
Study: 3552358

Group type: EXPERIMENTAL
Intervention: Propranolol (160 +/- 20 mg/day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Verapamil (450 +/- 30 mg/day)
Number of subjects: 8
Study: 29401192

Group type: EXPERIMENTAL
Intervention: Multi-ingredient preworkout supplement (SUP)
Number of subjects: 12
Study: 26614506

Group type: EXPERIMENTAL
Intervention: NO3 (‐)‐rich beetroot juice (BR; 8.2 mmol NO3‐ day(‐1))
Number of subjects: 10

Group type: COMPARATOR
Intervention: NO3 (‐)‐depleted beetroot juice (PL; 0.08 mmol NO3‐ day(‐1))
Number of subjects: 10
Study: 24272064

Group type: EXPERIMENTAL
Intervention: Kato-Katz method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ether-concentration technique
Number of subjects: 0